|1.||Miki, Tsuneharu: 3 articles (01/2010 - 12/2002)|
|2.||Mizutani, Yoichi: 3 articles (01/2010 - 12/2002)|
|3.||Kawauchi, Akihiro: 3 articles (01/2010 - 12/2002)|
|4.||Hirakawa, Kosei: 3 articles (02/2007 - 08/2002)|
|5.||Murawaki, Yoshikazu: 2 articles (05/2010 - 11/2007)|
|6.||Nagahara, Takakazu: 2 articles (05/2010 - 11/2007)|
|7.||Li, Yong Nan: 2 articles (01/2010 - 10/2004)|
|8.||Nakanishi, Hiroyuki: 2 articles (01/2010 - 10/2004)|
|9.||Sato, Nodoka: 2 articles (01/2010 - 10/2004)|
|10.||Tendo, Masashige: 2 articles (02/2007 - 07/2005)|
|1.||Urinary Bladder Neoplasms (Bladder Cancer)
10/01/2004 - "This study demonstrates that combination treatment of bladder cancer cells with the selective COX-2 inhibitor JTE-522 and CDDP results in synergistic cytotoxicity and apoptosis in vitro and in vivo. "
10/01/2004 - "These findings support the potential clinical application of a combination of JTE-522 and CDDP for the treatment of bladder cancer as a new form of therapy with more selective cytotoxicity and fewer collateral side effects."
10/01/2004 - "We examined whether the selective COX-2 inhibitor JTE-522 (4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide) synergizes with anticancer agents in cytotoxicity and apoptosis against bladder cancer cells in vitro and in vivo. "
12/01/2002 - "We examined whether the selective COX-2 inhibitor JTE-522 induces apoptosis in bladder cancer cells and whether JTE-522 may act synergistically with anticancer agents to achieve cytotoxicity and apoptosis in these cells. "
12/01/2002 - "This study shows that combination treatment of bladder cancer cells with the selective COX-2 inhibitor JTE-522 and 5-FU results in synergistic cytotoxicity and apoptosis due to the enhanced Bax-to-Bcl-XL expression ratio. "
02/01/2007 - "JTE-522 decreased COX-2 expression and Ki67 labeling index within the coinoculated tumor. "
07/01/2005 - "Finally, the effects of orally administrated JTE-522 on orthotopically transplanted tumors were examined in nude mice. "
03/03/2005 - "JTE-522 dose-dependently decreased lung weight (p = 0.001) and the size of pulmonary metastatic tumors (p = 0.0002). "
12/20/2004 - "JTE-522 interfered with the growth of hematogenous metastatic tumors by disrupting neovascularization. "
12/20/2004 - "JTE-522 reduced the diameter of tumor vessels as well as the number and size of metastatic tumors. "
|3.||Neoplasm Metastasis (Metastasis)
03/03/2005 - "JTE-522 dose-dependently decreased the size, but not the number of pulmonary metastases. "
12/20/2004 - "JTE-522 also affected type of vasculature of metastases, which differed depending on their size. "
12/20/2004 - "We investigated the effect of 0, 10 and 30 mg/kg/day of JTE-522 on the angiogenesis of pulmonary metastases in 3 groups of 5 male rats out of 25. "
01/01/2003 - "JTE-522 prevented the liver metastasis of HT-29, but not the subcutaneous growth of HT-29 and COLO205 in SCID mice. "
12/01/1999 - "Lung metastases were compared between groups with and without JTE-522. "
|4.||Colonic Neoplasms (Colon Cancer)
02/01/2005 - "We could clearly demonstrate that, in addition to the decrease of the proliferative activity, JTE-522 caused a dose-dependent decrease in both the ability of colon cancer cells to adhere to and to migrate on ECM. "
02/01/2005 - "In the present study, a high-COX-2 (high level COX-2 expression) colon cancer cell line, HT-29, and a low-COX-2 (low level COX-2 expression), DLD-1, were used to investigate the anticolon cancer effect of the selective COX-2 inhibitor, JTE-522. "
08/10/2002 - "These data indicate that the COX-2 inhibitor JTE-522 has a high potential for use as a clinical agent for the treatment of liver metastasis of colon cancer."
08/10/2002 - "We conclude that JTE-522 downregulated the cell proliferation and invasive potential of LM-H3 by reducing the production of PDGF and MMP-2 and hypothesize that these inhibitory effects on the production of PDGF and MMP-2 can lead to inhibition of liver metastasis of colon cancer. "
12/01/1999 - "Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522."
|5.||Colorectal Neoplasms (Colorectal Cancer)
12/20/2004 - "JTE-522, a selective COX-2 inhibitor, interferes with the growth of lung metastases from colorectal cancer in rats due to inhibition of neovascularization: a vascular cast model study."
03/03/2005 - "JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats."
12/20/2004 - "JTE-522 may be one of the therapeutic agents for the treatment of hematogenous metastasis of colorectal cancer."
12/20/2004 - "We investigated the microvascular structure of small lung metastases and the effect of JTE-522, a selective COX-2 inhibitor, on the angiogenesis of pulmonary metastases from colorectal cancer in rats. "
|2.||Cyclooxygenase 2 (Cyclooxygenase-2)
|3.||Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
|5.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|6.||N- (2- cyclohexyloxy- 4- nitrophenyl)methanesulfonamide
|7.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|1.||Combination Drug Therapy (Combination Chemotherapy)